FY2028 Earnings Estimate for ORKA Issued By Leerink Partnrs

Oruka Therapeutics, Inc. (NASDAQ:ORKA) – Analysts at Leerink Partnrs issued their FY2028 EPS estimates for shares of Oruka Therapeutics in a research report issued to clients and investors on Wednesday, November 13th. Leerink Partnrs analyst D. Risinger forecasts that the company will post earnings of ($2.92) per share for the year. Leerink Partnrs currently has a “Strong-Buy” rating on the stock. The consensus estimate for Oruka Therapeutics’ current full-year earnings is ($1.69) per share.

Other analysts have also issued research reports about the stock. Leerink Partners began coverage on shares of Oruka Therapeutics in a research report on Tuesday, September 17th. They set an “outperform” rating and a $44.00 target price on the stock. Jefferies Financial Group began coverage on Oruka Therapeutics in a report on Friday, September 13th. They issued a “buy” rating and a $40.00 price target for the company. Wedbush initiated coverage on shares of Oruka Therapeutics in a research report on Wednesday, September 4th. They set an “outperform” rating and a $40.00 target price on the stock. Lifesci Capital assumed coverage on Oruka Therapeutics in a report on Monday, September 16th. They issued an “outperform” rating and a $41.00 price target for the company. Finally, Stifel Nicolaus began coverage on shares of Oruka Therapeutics in a research report on Friday, October 11th. They issued a “buy” rating and a $49.00 target price for the company. Six investment analysts have rated the stock with a buy rating and two have given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Buy” and a consensus price target of $43.17.

Oruka Therapeutics Stock Down 6.4 %

NASDAQ ORKA opened at $24.00 on Friday. Oruka Therapeutics has a fifty-two week low of $18.72 and a fifty-two week high of $53.88. The business has a fifty day moving average of $26.78.

Institutional Investors Weigh In On Oruka Therapeutics

Hedge funds have recently added to or reduced their stakes in the stock. The Manufacturers Life Insurance Company acquired a new position in Oruka Therapeutics during the 3rd quarter worth $1,037,000. FMR LLC acquired a new stake in Oruka Therapeutics during the 3rd quarter worth about $114,763,000. Braidwell LP purchased a new stake in shares of Oruka Therapeutics in the third quarter valued at $12,640,000. Finally, Great Point Partners LLC acquired a new stake in shares of Oruka Therapeutics during the third quarter worth approximately $12,614,000. 56.44% of the stock is currently owned by institutional investors.

About Oruka Therapeutics

ARCA biopharma, Inc, a biopharmaceutical company, develops genetically-targeted therapies for heart failure and cardiovascular diseases. It is positioned to bring personalized therapies for the treatment of cardiovascular disease, through the use of genetics. Complementing the Company’s cardiovascular science, ARCA’s management team has significant experience in developing and commercializing cardiovascular products.